Zhiqing Liang
Overview
Explore the profile of Zhiqing Liang including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
99
Citations
923
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Su H, Xiao S, Liang Z, Xun T, Zhang J, Yang X
Front Pharmacol
. 2025 Feb;
15:1475222.
PMID: 39911832
Background: In contrast to previous network meta-analysis using classical frequentist methods, we evaluated the efficacy and safety of six frequently-used biologics through a Bayesian method. Methods: Web of Science, Scopus,...
2.
Yao Y, Luo X, Jiang P, Liu H, Wang Y, Deng L, et al.
Int J Gynaecol Obstet
. 2024 Dec;
PMID: 39636178
Objective: The purpose of this study was to establish a predictive model for endometrial cancer (EC) recurrence based on commonly used molecular markers and clinicopathologic parameters. Methods: This was a...
3.
Xie Y, Ye H, Liu Z, Liang Z, Zhu J, Zhang R, et al.
Biomolecules
. 2024 Nov;
14(11).
PMID: 39595613
The fundamental biological characteristics of tumor cells are characterized by irregularities in signaling and metabolic pathways, which are evident through increased glucose uptake, altered mitochondrial function, and the ability to...
4.
Wu X, Sun Y, Yang H, Wang J, Lou H, Li D, et al.
Lancet
. 2024 Oct;
404(10463):1668-1676.
PMID: 39426385
Background: Cadonilimab is a bispecific antibody targeting PD-1 and CTLA-4, which has shown substantial clinical benefits in advanced cervical cancer. In the COMPASSION-16 trial, we aimed to evaluate the addition...
5.
Tao M, Wu T, Zhou X, Du X, Ling K, Liang Z
Arch Gynecol Obstet
. 2024 Jul;
310(3):1315-1329.
PMID: 38980346
Objective: Levonorgestrel intrauterine system (LNG-IUS) has been widely used in patients with endometrial carcinoma (EC), endometrial hyperplasia without atypical (EH), and atypical endometrial hyperplasia (AEH). The purpose of our Network...
6.
Li H, Peng Z, Zhu J, Zhao W, Huang Y, An R, et al.
BMC Med
. 2024 May;
22(1):199.
PMID: 38755585
Background: The prospective phase III multi-centre L-MOCA trial (NCT03534453) has demonstrated the encouraging efficacy and manageable safety profile of olaparib maintenance therapy in the Asian (mainly Chinese) patients with platinum-sensitive...
7.
Wu X, Liu J, Wang J, Wang L, Lin Z, Wang X, et al.
Nat Med
. 2024 May;
30(6):1612-1621.
PMID: 38750351
Poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors as maintenance therapy after first-line chemotherapy have improved progression-free survival in women with advanced ovarian cancer; however, not all PARP inhibitors can provide benefit for...
8.
Deng L, Tang S, Dou Y, Li Y, Liang Z, Wang Y
Heliyon
. 2023 Jul;
9(8):e18389.
PMID: 37520954
Study Objective: To explore the effect of pretreatment with ureteroscopic triage for iatrogenic ureterovaginal fistula (UVF) resulting from radical hysterectomy. Design: A retrospective cohort study. Setting: Department of gynecology at...
9.
Ling K, Dou Y, Yang N, Deng L, Wang Y, Li Y, et al.
J Control Release
. 2023 Jul;
360:496-513.
PMID: 37423524
CRISPR/Cas9-based genome editing is promising for therapy of cervical cancer by precisely targeting human papillomavirus (HPV). To develop CRISPR/Cas9-based genome editing nanotherapies, a pH-responsive hybrid nonviral nanovector was constructed for...
10.
Huang Y, Wang K, Zhuo R, He X, Wu J, Wang H, et al.
Opt Express
. 2023 Feb;
31(2):929-947.
PMID: 36785141
Free-space optical (FSO) communication has attracted extensive attention in recent years. To maintain a reliable FSO link, two main issues need to be addressed: beam drift and vibration. In this...